Joyce O'Shaughnessy is an Oncology physician. ClinicalTrials.gov lists 17 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
3410 Worth St Ste 400
Dallas, TX 752462092
Telephone
214-370-1000Provider last certified this registry record 24 Apr 2025.
Clinical trials
17 registered studies on ClinicalTrials.gov matched to this name. Itemized trial rows, roles and sponsors are part of the full profile. Why? →
Industry payments
46 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Merck Sharp & Dohme LLCProgram year202514 payments$28,991openpaymentsdata.cms.gov ↗
- Eli Lilly and CompanyProgram year202525 payments$22,328openpaymentsdata.cms.gov ↗
- PFIZER INC.Program year20256 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
65.5%PD-1 inhibitor26%Pembrolizumab74%Nivolumab26%Part B, office-administered≥54 patientsMicrotubule Inhibitor11.2%Paclitaxel83%Docetaxel17%Part B, office-administered≥40 patients+ 13 more classes in this area
Metabolism & gastrointestinal
20.2%Other antiemetics17.6%Fosaprepitant100%Part B, office-administered≥83 patientsSerotonin-3 Receptor Antagonist2.4%Palonosetron hcl66%Granisetron hydrochloride33%Ondansetron Odt1%Part D + Part B≥104 patients+ 3 more classes in this area
Musculoskeletal
3.3%RANK Ligand Inhibitor3.1%Denosumab100%Part B, office-administered≥24 patientsBisphosphonate0.2%Zoledronic acid100%Part B, office-administered≥47 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Similar KOLs
Other experts from the same institution or the same specialty.
Freddie Bray
Centre National de la Recherche Scientifique
Jacques Ferlay
Centre international de recherche sur le cancer
Hermann Brenner
German Cancer Research Center
Isabelle Soerjomataram
Centre international de recherche sur le cancer
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”